R&D Shuffle Pushes Pfizer To Return Asthma Drug To Rigel Pharmaceuticals
This article was originally published in The Pink Sheet Daily
Executive Summary
The big pharma's decision to end allergy and respiratory R&D prompts it to return R343 to Rigel.